Nostrum agrees to $50M settlement with DOJ over allegations of underpaying Medicaidnews2023-10-31T18:31:57+00:00October 31st, 2023|Endpoints News|
Pfizer shelves five mid- and early-stage programsnews2023-10-31T18:21:24+00:00October 31st, 2023|Endpoints News|
FDA pushes cancer drug developers to include overall survival data more frequentlynews2023-10-31T17:19:45+00:00October 31st, 2023|Endpoints News|
Longtime cancer R&D chief Peter Lebowitz is taking his final bows at J&J oncology. Now what?news2023-10-31T16:38:13+00:00October 31st, 2023|Endpoints News|
Mersana’s STING agonist ADC back on track in PhI after FDA lifts clinical holdnews2023-10-31T15:33:25+00:00October 31st, 2023|Endpoints News|
Aragen to build $30M biologics facility in Indianews2023-10-31T15:28:50+00:00October 31st, 2023|Endpoints News|
Sarepta’s Duchenne confirmatory trial results set up showdown between FDA and company’s bold talknews2023-10-31T15:28:18+00:00October 31st, 2023|Endpoints News|
Galera considers ‘strategic’ options; Novo partners with French biotech; AnHeart gets $40Mnews2023-10-31T15:14:48+00:00October 31st, 2023|Endpoints News|
GSK buys J&J’s license to Arrowhead’s hepatitis B drug, plans combo studynews2023-10-31T15:03:28+00:00October 31st, 2023|Endpoints News|
Local pharmacies say they’re struggling to afford GLP-1snews2023-10-31T14:30:12+00:00October 31st, 2023|Endpoints News|
